A hundred and eighty three patients with a primary
myocardial infarction less than 4 hours old were included in a double blind trial versus placebo comparing an isolated
plasminogen streptokinase activator complex (
APSAC: 30 mu in 5 mn) and
tissue type plasminogen activator (rt
PA: 10 mg bolus followed by 90 mg in 130 mn). Clinical evolution, side effects, patency of the artery responsible for
infarction, left ventricular contractile function (contrast angiography on the 7th day and angioscintigraphy on the 21st day) and
infarct size were studied. The two groups were comparable in age (54 +/- 11 years), delay in randomisation (170 +/- 50 mn),
infarct site and severity of
cardiac failure. There was no significant difference in hospital mortality (7 in the rt PA group and 5 in the
APSAC group) or in adverse effects (haemorrhage: rt PA: 9 patients,
APSAC: 11 patients). The patency was 72% in the
APSAC and 76% in the rt PA group. Left ventricular function and
infarct size were comparable in the two groups: angiographic EF (0.50 +/- 0.1 in the
APSAC and 0.52 +/- 0.1 in the rt PA group: NS); asynergic score (11.3 +/- 1.7 in the
APSAC and 10.5 +/- 1.8 in the rt PA group: NS);
infarct size (10.9 +/- 8.0 in the
APSAC and 9.4 +/- 7.2 in the rt PA group: NS). This trial shows that these two
thrombolytic agents have the same efficacy. The authors recommend adaptation of the dosage of rt PA to
body weight.